OptiNose, Inc. (OPTN)
Fuera de horario:
OptiNose, Inc.
1020 Stony Hill Road
Suite 300
Yardley, PA 19067
United States
267 364 3500
https://www.optinose.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 132
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Ramy A. Mahmoud M.D., M.P.H. | CEO & Director | 1.12M | N/D | 1965 |
| Mr. Michael F. Marino Esq. | Chief Legal Officer & Corporate Secretary | 785.95k | N/D | 1976 |
| Mr. Paul Spence | Chief Commercial Officer | 664.02k | N/D | 1969 |
| Mr. Anthony J. Krick | VP of Finance & Chief Accounting Officer | N/D | N/D | 1981 |
| Mr. Jonathan Neely | Vice President of Investor Relations & Business Development | N/D | N/D | N/D |
| Ms. Karen E. Brophy | Chief Human Resources Officer & VP of Human Resources | N/D | N/D | 1963 |
Descripción
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Gestión corporativa
La calificación ISS Governance QuickScore de OptiNose, Inc. a partir del 1 de mayo de 2024 es 7. Las puntuaciones principales son Auditoría: 8; Junta: 6; Derechos del accionista: 8; Compensación: 7.
